Increased percentages of PD-1 on CD4⁺ T cells is associated with higher INF-γ production and altered IL-17 production in patients with systemic lupus erythematosus

References

• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787–93.
   PubMed Web of Science ®Google Scholar
• Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999;115:189–95.
   PubMed Web of Science ®Google Scholar
• Wan B, Nie H, Liu A, Feng G, He D, Xu R, Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844–50.
   PubMed Web of Science ®Google Scholar
• Saresella M, Marventano I, Longhi R, Lissoni F, Trabattoni D, Mendozzi L, CD4+CD25+FoxP3+PD1– regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J 2008;22:3500–8.
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515–48.
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–72.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027–34.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol 2001;2:261–8.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998;10:1563–72.
   PubMed Web of Science ®Google Scholar
• Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007;19:309–14.
   PubMed Web of Science ®Google Scholar
• Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003;30:1410–19.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren’s syndrome. J Rheumatol 2005;32:2156–63.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Takahashi H, Ishikawa T, Hokari A, Otsuki N, Azuma M, Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 2007;57:485–92.
   PubMed Web of Science ®Google Scholar
• Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S, Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol 2010;184:2337–47.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009;60:207–18.
   PubMed Web of Science ®Google Scholar
• Kristjansdottir H, Steinsson K, Gunnarsson I, Gröndal G, Erlendsson K, Alarcón-Riquelme ME. Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:1702–11.
   PubMed Web of Science ®Google Scholar
• Prokunina L, Castillejo-López C, Oberg F, Gunnarsson I, Berg L, Magnusson V, A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nature Genet 2002;32:666–9.
   PubMed Web of Science ®Google Scholar
• Liu M-F, Weng C-T, Weng M-Y. Variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus. J Biomed Biotechnol 2009;2009:406136.
   PubMedGoogle Scholar
• Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 2005;102:11823–8.
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004;101:10691–6.
   PubMed Web of Science ®Google Scholar
• Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, Tsai M, Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006; 176:2238–48.
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849–61.
   PubMed Web of Science ®Google Scholar
• Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000;165:5814–21.
   PubMed Web of Science ®Google Scholar
• Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000;11:2044–55.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008;43:402–7.
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2008; 58:2196–205.
   PubMed Web of Science ®Google Scholar
• Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9:461–7.
   PubMedGoogle Scholar
• Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Med 2007;13:1173–5.
   PubMed Web of Science ®Google Scholar
• Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Linking genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are increased in Crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008;14:204–12.
   PubMed Web of Science ®Google Scholar
• Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647–56.
   PubMed Web of Science ®Google Scholar
• Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009;60:1472–83.
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009;183: 4984–93.
   PubMed Web of Science ®Google Scholar
• Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nature Med 2010;16:452–9.
   PubMed Web of Science ®Google Scholar